Skip to main content
. 2023 Jan;64(1):109–116. doi: 10.2967/jnumed.122.263962

FIGURE 5.

FIGURE 5.

Selected bioluminescence images at varying times after treatment in experiment 4. Single treatment was given 4 d after injection of 106 tumor cells intravenously (8 animals per group). BLI and survival were assessed. Treatment groups included controls (no treatment), 10 μg of unlabeled rituximab, 3,700 kBq of 213Bi-rituximab, 2,035 kBq of 131I-tositumomab, and 1,295 kBq of 90Y-rituximab. Survival is prolonged in 213Bi and 131I anti-CD20 groups vs. controls and 90Y-rituximab.